Pfizer’s Toviaz safe, effective in treating overactive bladder in elderly patients
NEW YORK — A drug made by Pfizer appears to work in treating symptoms of overactive bladder in elderly patients, according to results of a clinical trial released Monday.
Pfizer said that results of study A0221049 of the drug Toviaz (fesoterodine fumarate) worked better than placebo in reducing the number of urgency urinary incontinence episodes. The 12-week study enrolled 562 elderly people in the United States. The drug already has Food and Drug Administration approval for treating overactive bladder.
"For older individuals with overactive bladder, incontinence accompanied by urgency is the symptom that is most bothersome and embarrassing and greatly impacts their overall quality of life," said Steven Romano, Pfizer SVP and head of the medicines development group of the company’s global primary care business unit. "Importantly, this was the first study of any antimuscarinic agent to demonstrate efficacy and safety in the rapidly growing population of medically vulnerable seniors who struggle with overactive bladder."
Study tracks development, integration of MTM
WASHINGTON — The concept of medication therapy management has become more developed, and certain aspects of it have become established within the organizations providing and paying for it, according to a white paper published in the Journal of the American Pharmacists Association.
Researchers from pharmacy schools at the University of Minnesota, the University of Iowa, the University of Southern California and the University of Oklahoma collected data for "environmental scans" from MTM providers and payers throughout the United States using self-administered online surveys conducted between 2007 and 2010.
The study found a need to integrate MTM between organizations and patients serviced, between partnering organizations and between collaborating healthcare providers and that "a ‘channel of distribution’ is emerging in which organizational relationships and cost efficiencies will be important considerations in the near term." The researchers suggested that customer portfolio management and transaction cost economics would help to integrate MTM into the U.S. healthcare system.
Click here to see the white paper.
Hi-Tech Pharmacal reports Q2
AMITYVILLE, N.Y. — Net sales for Hi-Tech Pharmacal rose 27% for its second quarter ended Oct. 31, the drug maker said.
Net sales for the three months were nearly $56.9 million, compared with about $44.7 million in the year-ago period. For its generic drug sales, Hi-Tech reported an increase of 33%, compared with second quarter 2012, which primarily was due to stronger sales of fluticasone propionate nasal spray. The company noted it also benefited from sales of gabapentin oral solution, ranitidine oral solution and lidocaine sterile jelly, all of which were launched this year, along with the company’s clobetasol line of topical products and buprenorphine.
Meanwhile, the company said its branded division, ECR Pharmaceuticals, contributed $3.5 million to sales in the current period, a decrease of $1.2 million, or 26%, compared with the year-ago period, mainly due to the discontinuation of the extended release versions in the Lodrane line of antihistamines. Increased sales of recently acquired products, including Tussicaps, partially offset the decrease in sales for the quarter, Hi-Tech Pharmacal said.